vs
Intellia Therapeutics, Inc.（NTLA）与Research Solutions, Inc.（RSSS）财务数据对比。点击上方公司名可切换其他公司
Intellia Therapeutics, Inc.的季度营收约是Research Solutions, Inc.的2.0倍（$23.0M vs $11.8M），Research Solutions, Inc.净利率更高（4.6% vs -416.2%，领先420.8%），Intellia Therapeutics, Inc.同比增速更快（78.8% vs -1.0%），Research Solutions, Inc.自由现金流更多（$1.4M vs $-69.4M），过去两年Research Solutions, Inc.的营收复合增速更高（-1.3% vs -10.8%）
Intellia Therapeutics是美国临床阶段生物技术企业，专注于依托CRISPR技术开发具有潜在治愈效果的创新疗法。公司体内项目采用静脉注射CRISPR疗法，通过专属递送技术可在特定靶组织内精准编辑致病基因；体外项目则利用CRISPR改造细胞制备治疗产品，主攻未被满足的医疗需求。
雅各布斯解决方案是一家总部位于美国达拉斯的国际技术专业服务企业，面向全球各类客户（包括企业、机构及政府部门）提供工程、技术、专业、建筑相关服务，以及科研与专项咨询服务，常年位居《工程新闻纪录》顶级设计企业榜单榜首。
NTLA vs RSSS — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $11.8M |
| 净利润 | $-95.8M | $546.9K |
| 毛利率 | — | 52.4% |
| 营业利润率 | -428.9% | 6.3% |
| 净利率 | -416.2% | 4.6% |
| 营收同比 | 78.8% | -1.0% |
| 净利润同比 | 25.7% | 127.6% |
| 每股收益（稀释后） | $-0.81 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $23.0M | $11.8M | ||
| Q3 25 | $13.8M | $12.3M | ||
| Q2 25 | $14.2M | $12.4M | ||
| Q1 25 | $16.6M | $12.7M | ||
| Q4 24 | $12.9M | $11.9M | ||
| Q3 24 | $9.1M | $12.0M | ||
| Q2 24 | $7.0M | $12.1M | ||
| Q1 24 | $28.9M | $12.1M |
| Q4 25 | $-95.8M | $546.9K | ||
| Q3 25 | $-101.3M | $749.4K | ||
| Q2 25 | $-101.3M | $2.4M | ||
| Q1 25 | $-114.3M | $216.5K | ||
| Q4 24 | $-128.9M | $-2.0M | ||
| Q3 24 | $-135.7M | $669.0K | ||
| Q2 24 | $-147.0M | $-2.8M | ||
| Q1 24 | $-107.4M | $76.3K |
| Q4 25 | — | 52.4% | ||
| Q3 25 | — | 50.6% | ||
| Q2 25 | — | 51.0% | ||
| Q1 25 | — | 49.5% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | — | 47.9% | ||
| Q2 24 | — | 46.5% | ||
| Q1 24 | — | 45.2% |
| Q4 25 | -428.9% | 6.3% | ||
| Q3 25 | -808.9% | 7.8% | ||
| Q2 25 | -772.2% | 9.7% | ||
| Q1 25 | -726.6% | 4.4% | ||
| Q4 24 | -1059.9% | 0.8% | ||
| Q3 24 | -1589.0% | 5.4% | ||
| Q2 24 | -1998.6% | 5.5% | ||
| Q1 24 | -394.0% | 0.7% |
| Q4 25 | -416.2% | 4.6% | ||
| Q3 25 | -735.2% | 6.1% | ||
| Q2 25 | -710.8% | 19.0% | ||
| Q1 25 | -687.6% | 1.7% | ||
| Q4 24 | -1001.2% | -16.6% | ||
| Q3 24 | -1489.5% | 5.6% | ||
| Q2 24 | -2112.6% | -23.3% | ||
| Q1 24 | -371.3% | 0.6% |
| Q4 25 | $-0.81 | $0.02 | ||
| Q3 25 | $-0.92 | $0.02 | ||
| Q2 25 | $-0.98 | $0.08 | ||
| Q1 25 | $-1.10 | $0.01 | ||
| Q4 24 | $-1.27 | $-0.07 | ||
| Q3 24 | $-1.34 | $0.02 | ||
| Q2 24 | $-1.52 | $-0.09 | ||
| Q1 24 | $-1.12 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $449.9M | $12.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $671.4M | $17.2M |
| 总资产 | $842.1M | $44.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $449.9M | $12.3M | ||
| Q3 25 | $511.0M | $12.0M | ||
| Q2 25 | $459.7M | $12.2M | ||
| Q1 25 | $503.7M | $9.9M | ||
| Q4 24 | $601.5M | $7.7M | ||
| Q3 24 | $658.1M | $6.9M | ||
| Q2 24 | $691.1M | $6.1M | ||
| Q1 24 | $791.3M | $4.2M |
| Q4 25 | $671.4M | $17.2M | ||
| Q3 25 | $748.4M | $15.6M | ||
| Q2 25 | $715.3M | $13.9M | ||
| Q1 25 | $779.9M | $11.2M | ||
| Q4 24 | $872.0M | $11.1M | ||
| Q3 24 | $962.6M | $12.8M | ||
| Q2 24 | $971.1M | $11.7M | ||
| Q1 24 | $1.0B | $14.1M |
| Q4 25 | $842.1M | $44.2M | ||
| Q3 25 | $925.3M | $45.5M | ||
| Q2 25 | $898.9M | $46.1M | ||
| Q1 25 | $986.2M | $45.2M | ||
| Q4 24 | $1.2B | $42.8M | ||
| Q3 24 | $1.2B | $41.4M | ||
| Q2 24 | $1.2B | $41.9M | ||
| Q1 24 | $1.3B | $40.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-69.3M | $1.4M |
| 自由现金流经营现金流 - 资本支出 | $-69.4M | $1.4M |
| 自由现金流率自由现金流/营收 | -301.6% | 11.7% |
| 资本支出强度资本支出/营收 | 0.5% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | $-395.9M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-69.3M | $1.4M | ||
| Q3 25 | $-76.9M | $1.1M | ||
| Q2 25 | $-99.6M | $2.3M | ||
| Q1 25 | $-148.9M | $2.9M | ||
| Q4 24 | $-85.2M | $1.0M | ||
| Q3 24 | $-84.8M | $843.1K | ||
| Q2 24 | $-58.2M | $2.0M | ||
| Q1 24 | $-120.7M | $2.0M |
| Q4 25 | $-69.4M | $1.4M | ||
| Q3 25 | $-76.9M | $1.1M | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-149.7M | $2.9M | ||
| Q4 24 | $-86.2M | — | ||
| Q3 24 | $-86.1M | — | ||
| Q2 24 | $-59.2M | $1.9M | ||
| Q1 24 | $-123.2M | $2.0M |
| Q4 25 | -301.6% | 11.7% | ||
| Q3 25 | -558.2% | 8.8% | ||
| Q2 25 | -701.0% | — | ||
| Q1 25 | -900.1% | 22.8% | ||
| Q4 24 | -669.4% | — | ||
| Q3 24 | -945.2% | — | ||
| Q2 24 | -850.9% | 16.0% | ||
| Q1 24 | -425.7% | 16.6% |
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 0.2% | 0.1% | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 4.4% | 0.0% | ||
| Q4 24 | 7.6% | — | ||
| Q3 24 | 14.0% | — | ||
| Q2 24 | 14.5% | 0.1% | ||
| Q1 24 | 8.7% | 0.0% |
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 13.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 26.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
RSSS
| Transactions | $6.6M | 56% |
| Platforms | $5.2M | 44% |
